Anti-VEGF reduces inflammatory features in macular edema secondary to retinal vein occlusion
Author:
Corresponding Author:

Guo-Xu Xu. Department of Ophthalmology, the Second Affiliated Hospital of Soochow University, 1055 Sanxiang Road, Outpatient Building, 4th Floor, Room E10, Suzhou 215004, Jiangsu Province, China. phacoxu@126.com; Jing-Fa Zhang. Department of Ophthalmology, Shanghai General Hospital (Shanghai First People’s Hospital), Shanghai Jiao Tong University, 100 Haining Road, Hongkou District, Shanghai 200080, China. 13917311571@139.com

Affiliation:

Clc Number:

Fund Project:

Supported by the National Natural Science Foundation of China (No.81970811; No.81970810; No.82171062); Domestic Science and Technology Cooperation Project of Shanghai Municipal Science and Technology Commission (No.21015800700).

  • Article
  • |
  • Figures
  • |
  • Metrics
  • |
  • Reference
  • |
  • Related
  • |
  • Cited by
  • |
  • Materials
  • |
  • Comments
    Abstract:

    AIM: To investigate the anti-inflammatory effect of intravitreal injection of anti-vascular endothelial growth factor (anti-VEGF) in patients with macular edema secondary to retinal vein occlusion (RVO-ME). METHODS: Twenty-eight eyes from twenty-eight treatment-naïve patients (14 males and 14 females) with RVO-ME were included in this retrospective study. The retinal vein occlusion (RVO) was comprised of both central retinal vein occlusion (CRVO, n=14) and branch retinal vein occlusion (BRVO, n=14). Intravitreal injection of anti-VEGF reagents were administered monthly for three consecutive months, in which 18 patients were injected with ranibizumab and 10 patients were injected with conbercept. All eyes were imaged with optical coherence tomography angiography (OCTA) at baseline and 1wk after monthly intravitreal anti-VEGF injection. The visual acuity (VA), central macular thickness (CMT), the number of hyperreflective foci (HRF) recognized as an inflammatory sign in OCT images, and non-perfusion area (NPA), were compared before and after anti-VEGF treatments. RESULTS: The mean interval between baseline and follow-up was 29.4±0.79 (range, 27-48)d. Compared with the baseline, the VA improved (logMAR 1.5±0.1 vs 0.8±0.1, P<0.05) and CMT decreased (460±34.0 μm vs 268.8±12.0 μm, P<0.05), significantly, after anti-VEGF treatment. The number of HRF was decreased significantly (76.5±4.8 vs 47.8±4.3, P<0.05) after anti-VEGF treatment. CONCLUSION: Anti-VEGF therapy is effective in treating RVO-ME. The mechanisms for the decreased HRF and the reduction of NPA by anti-VEGF therapy merits further exploration.

    Reference
    Related
    Cited by
Get Citation

Hai-Feng Qin, Fan-Jun Shi, Chao-Yang Zhang, et al. Anti-VEGF reduces inflammatory features in macular edema secondary to retinal vein occlusion. Int J Ophthalmol, 2022,15(8):1296-1304

Copy
Share
Article Metrics
  • Abstract:
  • PDF:
  • HTML:
  • Cited by:
Publication History
  • Received:October 31,2021
  • Revised:January 25,2022
  • Adopted:
  • Online: July 28,2022
  • Published: